Cite

HARVARD Citation

    Massachi, S. et al. (2021). Cost savings with hemin versus givosiran for the treatment of patients with acute intermittent porphyria (AIP). Journal of medical economics. pp. 1441-1449. [Online]. 
  
Back to record